Validation of RCC Predicting Model With Emulated-target Trial

Summary

This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .

Eligibility

Inclusion Criteria:

* Adults ≥18 years of age;
* Diagnosis of primary renal cell carcinoma before and during the surgery;
* Received radical nephrectomy/nephron-sparing surgery.

Exclusion Criteria:

* Subjects with severely missing clinical information;
* History of other malignant tumors.
* Recurrence observed before first postoperative follow-up.
* Discontinue the adjuvant treatment within in the first two course because of severe adverse react.

Conditions8

Browse More Trials